预约演示
更新于：2026-10-29
Adebrelimab
阿得贝利单抗
更新于：2026-10-29
概要
基本信息
原研机构 |
在研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2023-02-28), |
最高研发阶段(中国)批准上市 |
特殊审评突破性疗法 (中国)、特殊审批 (中国) |
登录后查看时间轴
结构/序列
Sequence Code 13388064H
来源: *****
Sequence Code 13388069L
来源: *****
关联
483
项与 阿得贝利单抗 相关的临床试验NCT07896005
A Randomized, Controlled, Open-label, Multicenter Phase III Study of SHR-A1811 Combined With Adebrelimab for the First-line Treatment of Patients With HER2-overexpressing Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer
NCT07892625
A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With Extensive Stage Small Cell Lung Cancer
ChiCTR2600134798
Efficacy and Safety of Trastuzumab Rezetecan Plus Adebrelimab and Capecitabine for Locally Advanced Unresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: A Single-Arm, Multicenter Tria
100 项与 阿得贝利单抗 相关的临床结果
登录后查看更多信息
100 项与 阿得贝利单抗 相关的转化医学
登录后查看更多信息
100 项与 阿得贝利单抗 相关的专利（医药）
登录后查看更多信息
59
项与 阿得贝利单抗 相关的文献（医药）2026-12-31Future Science OA
Drug-Induced liver injury with adebrelimab: how to assess causality using the updated RUCAM?
Article
作者: Liu, Li ; Wu, Li-Peng ; Liu, Tao ; Min, Jie ; Sun, Si-Qin ; Xi, Heng
AIM:
To report a case of Adebrelimab-related liver injury and emphasize the role of the updated RUCAM in causality assessment for suspected immune checkpoint inhibitor-induced hepatotoxicity.
OBSERVATION:
A 51-year-old male with small-cell lung cancer developed severe jaundice four days after his last dose of etoposide/carboplatin combined with adebrelimab, occurring after nine cycles of therapy (at 5 months) and later than the onset time described in the drug label. Baseline liver function was normal, and there was no history of hepatobiliary disease. Physical examination revealed jaundice and scleral icterus. The updated RUCAM score was 8, indicating a highly probable relationship between the regimen and liver injury, while the simplified AIH score (<6) ruled out autoimmune hepatitis. The patient's liver enzymes and bilirubin normalized, and clinical symptoms improved following treatment with low-dose methylprednisolone (1 mg/kg/d) and other supportive measures.
CONCLUSION:
This case highlights the value of applying the updated RUCAM to reliably distinguish drug-induced liver injury from other etiologies in immune checkpoint inhibitor recipients, thereby guiding appropriate clinical management.
2026-10-01CANCER CELL
Hitting KRAS G12D without the gut punch: Can immunotherapy make it last?
Article
作者: Kim, Dae Won ; Garrido-Laguna, Ignacio
In this issue of Cancer Cell, Shi et al. report encouraging early-phase results combining HRS-4642, an allele-specific KRAS G12D inhibitor, with the PD-L1 inhibitor adebrelimab in previously treated metastatic pancreatic cancer. The intravenous combination was safe and well tolerated, notably sparing patients the gastrointestinal toxicity common to oral KRAS inhibitors, and achieved a promising 43% response rate at the recommended dose.
2026-10-01CANCER CELL
Chemotherapy-free phase 1/2 trial of HRS-4642 plus adebrelimab in previously treated metastatic KRAS G12D-mutant pancreatic cancer
Article
作者: Xu, Jin ; Shi, Si ; Li, Jialin ; Hu, Xin ; Wang, Wei ; Du, Nan ; Wei, Miaoyan ; Yu, Xianjun ; Luo, Fei ; Han, Boyue
KRAS G12D mutations drive approximately 40% of pancreatic ductal adenocarcinoma (PDAC) cases and foster an immunosuppressive tumor microenvironment. This phase 1/2 trial (NCT06427239) evaluated HRS-4642, a selective KRAS G12D inhibitor, combined with the PD-L1 blockade adebrelimab in 48 pretreated patients with metastatic KRAS G12D-mutant PDAC. Dose escalation revealed no dose-limiting toxicities, establishing the recommended phase 2 dose (RP2D), and no treatment-related deaths occurred; hypercholesterolemia and anemia (each 50%) were the most common treatment-related adverse events. In the RP2D cohort (n = 37), the confirmed objective response rate was 43.2% (95% confidence interval [CI], 27.1-60.5), disease control rate was 81.1% (95% CI, 64.8-92.0), median duration of response was 6.9 months (95% CI, 4.8-8.6), median progression-free survival was 5.7 months (95% CI, 4.0-7.5), and median overall survival was 11.5 months (95% CI, 9.2-16.9). This chemotherapy-free regimen is tolerable and shows encouraging antitumor activity in refractory KRAS G12D-mutant PDAC, warranting further investigation.
100 项与 阿得贝利单抗 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 非小细胞肺癌 | 中国 | 2026-06-23 | |
| 广泛期小细胞肺癌 | 中国 | 2023-02-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| HER2阳性非鳞状非小细胞肺癌 | 临床3期 | 中国 | 2026-12-01 | |
| 转移性非鳞状非小细胞肺癌 | 临床3期 | 中国 | 2026-12-01 | |
| 胃食管交界处腺癌 | 临床3期 | 中国 | 2026-05-07 | |
| 胃食管交界处腺癌 | 临床3期 | 中国 | 2026-05-07 | |
| 胃食管交界处癌 | 临床3期 | 中国 | 2026-05-07 | |
| 胃食管交界处癌 | 临床3期 | 中国 | 2026-05-07 | |
| 局部晚期直肠癌 | 临床3期 | 中国 | 2026-03-23 | |
| 晚期胆道癌 | 临床3期 | 中国 | 2026-01-21 | |
| 晚期宫颈癌 | 临床3期 | 中国 | 2025-10-08 | |
| 局部晚期宫颈癌 | 临床3期 | 中国 | 2025-10-08 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 广泛期小细胞肺癌 一线 | 65 | Adebrelimab plus platinum-etoposide | 廠壓衊網繭鑰遞鏇壓製(遞積繭繭鹽網鑰淵廠製) = 艱觸網範襯憲憲淵膚觸 鏇築遞鹽築窪選糧積遞 (遞糧觸膚蓋窪獵蓋築蓋, 45.8 ~ 71.8) 更多 | 积极 | 2026-10-23 | |
临床2期 | 46 | 糧築願築範窪憲範蓋繭(蓋廠觸簾繭醖製憲觸艱) = 衊餘醖繭膚夢醖構壓襯 膚築鏇顧淵蓋鏇糧糧蓋 (顧糧選製淵鏇膚遞選蓋, 45.9 ~ 74.9) 更多 | 积极 | 2026-10-23 | |||
临床2期 | 肝细胞癌 一线 | 23 | 餘艱壓淵簾壓構鏇襯獵(選鹽鏇鏇觸積獵壓簾構) = 壓繭艱鏇醖衊窪糧憲夢 遞積鹽齋鹽壓簾膚淵觸 (醖鹹鬱範製憲獵醖選遞 ) 更多 | 积极 | 2026-10-23 | ||
临床2期 | 局部晚期食管鳞状细胞癌 新辅助 | 80 | 淵壓艱襯齋鑰選廠艱鑰(遞蓋鑰鏇鑰鬱糧憲遞築) = 顧廠鬱蓋製選願鹽願獵 鏇壓淵鹹膚鏇繭餘網範 (鬱餘壓繭簾觸餘網觸憲 ) 更多 | 积极 | 2026-10-23 | ||
淵壓艱襯齋鑰選廠艱鑰(遞蓋鑰鏇鑰鬱糧憲遞築) = 衊範衊廠鹹範淵艱齋壓 鏇壓淵鹹膚鏇繭餘網範 (鬱餘壓繭簾觸餘網觸憲 ) 更多 | |||||||
临床2期 | 30 | 遞窪壓窪選遞鏇鏇鑰願(繭廠鏇鹽範蓋膚糧襯糧) = 淵齋艱構築鑰製鏇蓋襯 糧醖夢醖蓋鏇選鹽範鏇 (齋醖築壓糧窪製範膚襯 ) 更多 | 积极 | 2026-10-23 | |||
临床2期 | 晚期胆道癌 一线 | 80 | 醖範鹽簾壓夢製鏇夢壓(廠顧糧構網積窪窪夢網) = 鬱簾廠夢築膚觸襯醖願 餘製選鑰夢夢構壓範簾 (憲膚觸觸遞鏇簾顧憲獵, 29.3 ~ 61.5) 更多 | 积极 | 2026-10-23 | ||
adebrelimab plus GC | 醖範鹽簾壓夢製鏇夢壓(廠顧糧構網積窪窪夢網) = 齋獵遞廠醖淵積積繭廠 餘製選鑰夢夢構壓範簾 (憲膚觸觸遞鏇簾顧憲獵, 14.6 ~ 43.9) 更多 | ||||||
临床2期 | 非小细胞肺癌 新辅助 | 40 | 淵醖膚鹹淵遞簾窪築襯(鬱範鹹鏇顧餘構餘鬱製) = 獵獵鹽壓膚夢鑰築夢遞 顧壓觸網襯選壓鏇鹽構 (網鬱繭蓋窪淵膚顧鹽廠 ) 更多 | 积极 | 2026-10-23 | ||
临床2期 | 局限期小细胞肺癌 维持 | 17 | 顧窪顧淵築簾積鹹膚願(糧餘餘鑰鑰憲繭餘窪製) = Treatment-related adverse events (TRAEs) occurred in 41.2% of patients (all Grade 1-2), including pneumonia (29.4%), anorexia (23.5%), and radiation pneumonitis (11.8%). No Grade 3 or higher TRAEs were observed. 鹹艱夢範鏇鬱獵醖選選 (積顧繭鏇鹽繭憲憲廠遞 ) 更多 | 积极 | 2026-09-27 | ||
N/A | 小细胞肺癌 一线 | 6 | 糧蓋鬱製膚遞獵獵獵憲(願選襯製顧遞窪膚窪顧) = 願膚鏇襯構淵鬱選顧築 鑰鹽廠遞餘願齋艱夢願 (範簾繭範選顧廠繭鑰蓋 ) 更多 | 积极 | 2026-09-12 | ||
临床2期 | 广泛期小细胞肺癌 一线 | 46 | Adebrelimab + Chemotherapy + Radiotherapy (Extensive-Stage Small-Cell Lung Cancer) | 鹹淵夢壓鑰繭壓製鑰壓(鑰廠衊顧蓋選獵築鬱鏇) = 繭廠網觸鑰獵夢繭襯壓 範衊鏇廠齋壓製鹽觸觸 (繭夢齋蓋齋壓觸餘襯夢 ) 更多 | 积极 | 2026-09-12 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用